BioSpace News Archive

The reverse stock split will become effective on Wednesday, July 17, 2019 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company’s existing trading symbol, “CUR,” at the market open on Thursday, July 18, 2019.

Patented technology filters health data to provide clinicians with point-of-care access to relevant information for optimal decision-making

the world’s leading chemical vendor BOC Sciences announced to upgrade its chiral analysis and separation service for the pharmaceutical industry to support scientists’ needs arising from drug testing after all the preliminary work of lead discovery in the early stages.

Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing.

EKF Diagnostics, the global in vitro diagnostics company, announces that its Quo-Test®HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR).

Research reported today at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles identified a number of differences in the progression and risk of Alzheimer’s disease between women and men, including newly identified sex-specific risk genes and contrasting presentation of Alzheimer’s biology in the brain.

Echosens, a high-technology company offering the FibroScan family of products, today announces the release of its white paper “The Economic Tsunami of Liver Disease,” articulating how a disease once considered uncommon in the 1980s is now a major epidemic.

The rate of violence in healthcare is five times greater than private industry on average; bill requires violence prevention programs

TrialCard Incorporated, an industry leader in access, affordability, adherence, and engagement solutions for patients and healthcare providers, today announced the appointment of Karen L. Russell as Chief Financial Officer (CFO), effective immediately

After comparing themselves to the industry standard, Novus Health has found they’re approximately 75% more affordable than a traditional EAP.